Full-Time

Clinical Research Associate

Posted on 11/1/2025

Agilent Technologies

Agilent Technologies

10,001+ employees

Provides eProcurement automation and hosted catalogs

Compensation Overview

$62.6k - $117.3k/yr

+ Bonus + Stock

Company Does Not Provide H1B Sponsorship

Pennsylvania, USA

Hybrid

Category
Biology & Biotech (7)
, , , , , ,
Requirements
  • Bachelor's degree or higher, or equivalent credentials
  • Knowledge of International Council for Harmonisation (ICH)/GCP guidelines, 21 CFR (Code of Federal Regulations) part 812 (lnvestigational Device Exemption) (IDE)), and monitoring procedures/best practices (ICH E6(R2))
  • Demonstrating strong written and verbal communication skills and presentation skills
  • Track record demonstrating strong organizational and problem-solving skills
  • Track record demonstrating a strong work ethic and ability to deliver tasks on time
  • Proficient with Microsoft Office Suite including automation tools
  • For CRA: 1+ years direct clinical research experience at a sponsor, CRO, device manufacturer
  • Experience with Electronic Data Capture (EDC) systems and eTMF systems
Responsibilities
  • Performs all study monitoring visits and completes supporting visit reports, including applicable visits such as site/investigator qualification, site initiation, interim monitoring, remote monitoring, and close-out visits
  • Trains investigator(s) and site staff on study protocol and all relevant study procedures
  • Supports study start-up, conduct, and closeout activities. May assist in developing study­ related plans and documents including clinical protocol, development of CRFs, reviewing informed consent forms, monitoring plan, etc. May coordinate IRB/EC approvals
  • Functions independently in the field and interacts professionally with all levels of medical and scientific professionals
  • Identify early on any unsatisfactory results, operations or specific problems and take immediate action to appropriate groups including escalating and assisting in resolving any study related issues that arise during study conduct
  • Assures adherence to GCP, study protocol, procedures, all applicable requirements, and regulations throughout the study monitoring visits. Responsible for implementing and maintaining the effectiveness of the quality system
  • Collect and review site regulatory and essential documents for accuracy and completion. Maintain the study Trial Master File (TMF)/or eTMF and ensure the Investigator Site Files (ISFs) are current and maintained
  • Perform Source Data Verification (SDV) and data cleaning in accordance with study monitoring plan. Reviewing all study logs and documentation ensuring audit trail and chain of custody is maintained
  • Performs Investigation Use Only (IUO) inventory and accountability, in accordance with study monitoring plan. Facilitates return or destruction of any unused IUO material as required
  • Serve as the primary point of contact for assigned sites and works with sites to resolve data queries and monitoring findings. Maintains accurate and timely communications with sites and ensures records are filed in TMF/ISF
  • Ensures TMF/ISF is audit ready. Assists with site audit(s) and site quality management activities, as needed. Tracks site progress against contractual agreements
  • Contribute to organizational and departmental process development, improvement, and implementation
Desired Qualifications
  • Bachelor's degree in biological sciences or medical specialty or higher, or equivalent credentials
  • Molecular diagnostic, medical device, in vitro diagnostic (IVD), companion diagnostics, oncology and/or pathology experience
  • Previous experience with Next Generation Sequencing (NGS), Immunohistochemistry (IHC), and/or pathology

Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Eight FDA-approved PD-L1 IHC 22C3 pharmDx indications drive companion diagnostics revenue.
  • AI-enabled imaging software differentiates Agilent amid sector vulnerability to funding fluctuations.
  • Analysts project $8.6 billion revenue and $2 billion earnings by 2029.

What critics are saying

  • Biocare integration failure destroys $200–300M expected value within 12–24 months.
  • Supreme Court CRISPR patent denial enables competitors to develop rival enrichment workflows.
  • Research funding contraction cuts recurring consumables revenue $200–600M annually within 12–18 months.

What makes Agilent Technologies unique

  • Biocare Medical acquisition adds 300+ specialized antibodies with double-digit growth since 2021.
  • BioTek Cytation 9 combines high-content imaging with automation for research labs.
  • Oxford Nanopore partnership enables structural variant analysis and methylation profiling applications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Company News

Yahoo Finance
Apr 3rd, 2026
Agilent loses CRISPR patent case but launches BioTek Cytation 9 imaging platform

Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.

Business Wire
Mar 26th, 2026
Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in esophageal or GEJ carcinoma

Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.

Yahoo Finance
Mar 23rd, 2026
Agilent leads research tools stocks with $1.8B Q4 revenue, up 7% amid sector decline

Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.

GS MedTech
Mar 9th, 2026
Agilent Technologies acquires US firm BioTek Instruments

Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t

Agilent Technologies
Mar 9th, 2026
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million.  Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction

INACTIVE